Entrada Therapeutics (TRDA) Return on Capital Employed (2021 - 2026)

Entrada Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 52.9% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 5374.0% year-over-year to 52.9% in Q1 2026; TTM through Mar 2026 was 52.9%, a 5374.0% decrease from a year earlier, with the FY2025 full-year figure at 36.94%, down 4720.0% from the prior year.
• Return on Capital Employed slipped to 52.9% in Q1 2026 per TRDA's latest filing, from 42.6% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 20.29% in Q2 2024 and bottomed at 52.9% in Q1 2026.
• The 5-year median for Return on Capital Employed is 21.47% (2025), against an average of 17.07%.
• Across the five-year window, Return on Capital Employed soared 4491 bps in 2024 and plunged 5374 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 40.3% in 2022, then soared by 98 bps to 0.99% in 2023, then soared by 1045 bps to 9.38% in 2024, then plunged by 554 bps to 42.6% in 2025, then fell by 24 bps to 52.9% in 2026.
• Per Business Quant, the three latest TRDA Return on Capital Employed figures stand at 52.9% (Q1 2026), 42.6% (Q4 2025), and 29.88% (Q3 2025).